What Does Eli Lilly (LLY) Do?

Eli Lilly (LLY), founded in Indianapolis in 1876, is one of America's oldest and most valuable pharmaceutical companies. The global demand explosion for its tirzepatide-based drugs Mounjaro (diabetes) and Zepbound (obesity) in 2023–2024 propelled Lilly's market capitalization from roughly $100 billion to over $800 billion in just a few years.

What Is It and What Does It Do?

Eli Lilly's product portfolio is concentrated across several key therapeutic areas:

• Metabolic Disease (GLP-1): Mounjaro (type 2 diabetes, tirzepatide) and Zepbound (obesity, tirzepatide) — the beating heart of the company's growth engine.
• Oncology: Verzenio (breast cancer), Jaypirca, and other cancer medications.
• Neurology: Kisunla (Alzheimer's — approved 2024, among the first disease-modifying Alzheimer's drugs).
• Immunology: Taltz (psoriasis) and Olumiant (rheumatoid arthritis).

Why Does It Matter?

• The GLP-1 revolution: Tirzepatide showed an average 22% reduction in body weight in clinical trials, breaking new ground in obesity treatment. Given global obesity prevalence, the addressable market is estimated in the trillions of dollars.
• Alzheimer's opportunity: Kisunla's approval positions Lilly as a significant player in the nascent Alzheimer's drug market.
• Manufacturing capacity: Global GLP-1 demand has outpaced supply; Lilly is investing billions to expand production capacity. Manufacturing ramp speed is the most critical near-term variable.
• Patent protection: Tirzepatide's patent protection extends into the mid-2030s, shielding it from generic competition during that period.

Eli Lilly GLP-1 drug family growth chart — quarterly revenue trend for Mounjaro and Zepbound; market share comparison with Novo Nordisk

How is LLY traded?

The underlying (LLY) trades on its own market during that market's session hours.

LLY price and technical analysis →

Risks

• GLP-1 concentration: A large share of revenue depends on a single drug family (tirzepatide); adverse clinical data or safety issues could have a severe impact.
• Novo Nordisk competition: Denmark's Novo Nordisk, maker of Ozempic and Wegovy, is Lilly's closest rival in the GLP-1 market.
• Pricing pressure: The U.S. government's drug price negotiation authority under the Inflation Reduction Act could extend to Lilly products.
• Manufacturing capacity ceiling: If supply remains constrained against surging demand, potential revenue cannot be fully realized.

COINOTAG Perspective

Eli Lilly is living one of the strongest corporate momentum stories in recent years. The GLP-1 drug revolution presents a historically rare opportunity against the backdrop of the global obesity epidemic, and Lilly's Alzheimer's and oncology portfolios provide further diversification. At elevated valuation multiples, some GLP-1 growth expectations are already priced in; manufacturing capacity and pricing policy will be the key sources of near-term volatility.